Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer
Evaluation of the pharmacokinetic equivalence of two Docetaxel formulations in terms of AUC and Cmax
Solid Tumor
DRUG: Docetaxel-PNP|DRUG: Taxotere
Pharmacokinetics of DocetaxelPNP and Taxotere in terms of Area Under the Curve (AUC), 3 months
Elimination Half Life (T1/2) of DocetaxelPNP and Taxotere, 3 months|Clearance (CL) of DocetaxelPNP and Taxotere, 3 months|Volume of Distribution at steady state (Vdss) of DocetaxelPNP and Taxotere, 3 months|Number of participants with Adverse Events, 3 months
Comparison of pharmacokinetic parameters (T1/2Î², CL, Vdss) Safety as measured by adverse events